CardiovascularStudy Shows EVISTA(R) Improves Patient Compliance In Osteoporosis Management
Data presented today at the 8th European Congress on Menopause
(EMAS) demonstrated that the majority of osteoporosis patients treated with
EVISTA(R) (raloxifene) stay on therapy for the first two years.
300 postmenopausal osteoporosis patients received oral
treatment with EVISTA(R). Patients were considered compliant if they had
taken at least 80% of their medication.[1] Prof. Dr. P. Hadji, University
Hospital of Giessen and Marburg GmbH, Marburg, Germany, said that "Results
show that at 12, 24 and 36 months 96.4 %, 80.5% and 62% respectively of
patients remained on therapy. The mean MPR was 52.8%. Finally 38.5% of all
patients were classified adherent".
The treatment of osteoporosis among postmenopausal women
represents a major public health challenge because long-term therapy is
required to prevent fractures and chronic disability.[2] Today"s results
highlight the importance of good treatment compliance to help achieve
therapeutic benefits for patients, and reduce the burden that osteoporosis
places on individuals and the healthcare system.[3]
"Poor adherence has a negative effect on patient outcomes, and
current treatment with many osteoporosis therapies tends to be suboptimal,"
commented Prof. Dr. P. Hadji, "However, EVISTA(R) has a long and proven
history of patient compliance. Years of research not only confirm that
patients adhere to treatment regimens with the drug, but also demonstrate a
safety profile that is as strong now as it was when EVISTA(R) first came to
market."
The data released today at EMAS comes in advance of
EVISTA(R)"s 10th anniversary, a turning point that will not go unmarked.
Coinciding with World Osteoporosis Day this October, plans are already
underway to highlight EVISTA(R)"s continued success as a treatment for
postmenopausal women with osteoporosis. Reinhard Bauer, DEO of DAIICHI SANKYO
EUROPE, said "DAIICHI SANKYO is delighted to mark the 10th anniversary of
EVISTA(R) later this year. The anniversary is intended to raise awareness of
the disease and highlight the role that EVISTA(R) has played in transforming
osteoporosis management over the years."
About EVISTA(R)
EVISTA(R) is a type of prescription medication called a
Selective Estrogen Receptor Modulator (SERM). It is indicated for the
treatment and prevention of osteoporosis in postmenopausal women. EVISTA(R)
treats and prevents osteoporosis by reducing the risk of vertebral
fractures.[4] EVISTA(R) has been taken by up to 26 million women worldwide,
up to 7 million of them were treated in Europe.[5]
About DAIICHI SANKYO
DAIICHI SANKYO is a global pharmaceutical company that focuses
on researching and marketing innovative medications. The company was created
in 2005 through the merger of two traditional Japanese enterprises, Daiichi
and Sankyo. With net sales of nearly 5.9 billion EUR in fiscal year 2008,
DAIICHI SANKYO is one of the world"s 20 leading pharmaceutical companies. The
company"s world headquarters is in Tokyo, and its European base is located in
Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been
one of the strongest Japanese pharmaceutical companies located in Europe
since it set up European production facilities and marketing offices in 1990.
The company"s research activities focus on the areas of cardiovascular
diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to
develop medications that are "best" in their class or to create new classes
of pharmaceutical drugs.
For more information, please visit:
http://www.daiichi-sankyo.eu
References:
[1]. Hadji P, Wetzel K, Ziller V et al. (2009) Compliance during
osteoporosis therapy with raloxifene. Poster presented at EMAS 2009
[2]. Turbi C, Herrero-Beaumont G, Acebes JC et al. (2004) Compliance and
Satisfaction with Raloxifene Versus Alendronate for the Treatment of
Postmenopausal Osteoporosis in Clinical Practice: An Open-Label, Prospective,
Nonrandomized, Observational Study. Clin Therap 26; 245-256
[3]. Siris ES, Selby PL, Saag KG et al. (2009) Impact of Osteoporosis
Treatment Adherence on Fracture Rates in North America and Europe. The
American Journal of Medicine (2009) 122, S3-S13
[4]. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD, (2002)
Early effects of raloxifene on clinical vertebral fractures at 12 months in
postmenopausal women with osteoporosis. Arch Intern Med.;162(10):1140-3.
[5]. Periodic safety Update Report, PSUR 16 Global (10-DEC-2007 TO 09-JUN
2008)/ Data on File
DAIICHI SANKYO